Breaking the Desmoplastic Shield: The Role of Repurposed Drugs and Supplements (2026)
Cancer is not simply a mass of malignant cells. In some tumors—especially pancreatic ductal adenocarcinoma—the cancer grows inside a dense, fibroinflammatory ecosystem that can influence blood flow, drug delivery, immune activity and treatment resistance. This article examines whether repurposed drugs and selected supplements could help remodel rather than simply destroy this protective tumor microenvironment.
Desmoplasia Cancer-associated fibroblasts Tumor microenvironment Pancreatic cancer Repurposed drugs Vitamin D
- What is desmoplasia?
- How the desmoplastic shield protects tumors
- Why the goal may be normalization, not destruction
- Losartan and stromal remodeling
- Vitamin D and the cancer-associated fibroblast
- Metformin and metabolic remodeling
- Ivermectin: promising biology, limited clinical evidence
- Mebendazole and fenbendazole
- Supplements under investigation
- The combination strategy
- Evidence hierarchy
- Where the field is heading
- Frequently asked questions
What Is Desmoplasia?
Desmoplasia is the formation of dense fibrotic and connective tissue around a tumor. It is particularly prominent in pancreatic ductal adenocarcinoma (PDAC), but related fibroinflammatory responses occur in several other cancers.
The tissue surrounding a tumor is called the tumor microenvironment (TME). It includes cancer-associated fibroblasts (CAFs), extracellular matrix proteins, blood vessels, immune cells, signaling molecules and metabolic components.
Modern cancer biology increasingly recognizes that these non-cancer cells are not merely passive scaffolding. They communicate with malignant cells and can influence tumor growth, invasion, immune suppression and therapeutic response.
A 2025 review in Nature Reviews Clinical Oncology described the pancreatic tumor microenvironment as a major barrier to the access of systemic therapies and circulating immune cells. Importantly, the review also emphasizes that the extracellular matrix and fibroblast populations are heterogeneous and can have both tumor-promoting and tumor-restraining functions.
How the Desmoplastic Shield Can Protect Cancer
A dense tumor microenvironment can influence cancer through several interconnected mechanisms.
1. Abnormal extracellular matrix
Collagen, fibronectin, hyaluronan and other extracellular matrix components create a mechanically altered environment. The matrix can change how cancer cells behave and how therapeutic molecules move through tissue.
2. Cancer-associated fibroblasts
CAFs are activated fibroblast populations that produce extracellular matrix and signaling molecules. Importantly, CAFs are not a single uniform cell type. Different subpopulations can have different—and sometimes opposing—effects on tumor biology.
3. Abnormal blood vessels
Tumor-associated vascular abnormalities can contribute to poor perfusion and uneven delivery of oxygen and drugs.
4. Hypoxia and metabolic stress
Poor oxygenation can alter tumor metabolism and signaling. Hypoxic regions may become more resistant to treatment and can influence immune-cell function.
5. Immune exclusion
A fibroinflammatory microenvironment can contribute to an immunologically “cold” tumor in which effective T-cell infiltration and activity are impaired.
These mechanisms do not operate independently. Fibroblasts, macrophages, tumor cells, extracellular matrix and blood vessels continuously communicate with one another.
Why the Goal May Be Normalization, Not Destruction
One of the most important lessons from stromal research is that more aggressive destruction of the tumor stroma is not automatically better.
Some stromal components can restrain tumor growth. Experimental depletion of particular fibroblast populations has, in some models, produced more aggressive disease. This illustrates why a simplistic “remove all fibroblasts” strategy can be biologically dangerous.
The emerging concept is therefore stromal normalization or reprogramming: change the tumor microenvironment so that it becomes less supportive of cancer, more accessible to therapy and potentially more permissive to immune-cell activity.
Do not necessarily destroy the entire shield.
Reprogram the shield.
Losartan and Stromal Remodeling
Losartan is an angiotensin II receptor blocker commonly used to treat hypertension. It has attracted interest in oncology because the renin-angiotensin system can influence fibrosis, extracellular matrix formation and tumor perfusion.
This provides a particularly interesting example of drug repurposing for the tumor microenvironment.
The biological rationale
Angiotensin signaling can promote pathways associated with fibrosis and stromal activation. Blocking the angiotensin II receptor may therefore alter the extracellular matrix and potentially improve vascular function and drug penetration.
What happened clinically?
A single-arm phase 2 trial evaluated FOLFIRINOX plus losartan followed by chemoradiotherapy in 49 patients with locally advanced pancreatic cancer. The study reported an R0 resection rate of 61% among eligible patients, with a median overall survival of 31.4 months.
These results were encouraging, but the study was not randomized. FOLFIRINOX, chemoradiotherapy, patient selection and multidisciplinary surgical management were all part of the treatment strategy. Therefore, the results cannot establish that losartan itself caused the improved outcomes.
Subsequent randomized research has been important because the question is whether adding losartan to chemotherapy actually improves patient outcomes compared with chemotherapy alone.
Vitamin D and the Cancer-Associated Fibroblast
Vitamin D biology provides another interesting example because the vitamin D receptor (VDR) is expressed in cells within the pancreatic tumor stroma.
Preclinical research has shown that vitamin D receptor activation can influence pancreatic stellate cells and stromal inflammation. A landmark study reported that the vitamin D analogue calcipotriol could promote a more quiescent stromal phenotype and improve chemotherapy delivery in experimental pancreatic cancer models.
More recent research continues to investigate how vitamin D signaling influences pancreatic stellate cells, cancer-associated fibroblasts and stromal signaling.
However, there is an important distinction between vitamin D biology and taking vitamin D supplements as a cancer treatment.
The National Cancer Institute notes that randomized trials have generally not shown vitamin D supplementation to prevent cancer incidence. Vitamin D analogues and vitamin D-based strategies remain subjects of clinical research in cancer treatment.
Metformin and Metabolic Remodeling
Metformin is another repurposed drug frequently discussed in metabolic oncology.
Its potential relevance comes from its effects on cellular energy metabolism, insulin signaling and related pathways. Because cancer cells, stromal cells and immune cells compete and cooperate within a metabolically constrained environment, metabolic interventions are being investigated as possible components of combination therapy.
However, observational associations between metformin use and cancer outcomes do not prove anticancer efficacy. Randomized evidence has been mixed, and metformin should not currently be presented as a general-purpose cancer treatment.
Its most interesting future role may therefore be biomarker-guided combination therapy, rather than indiscriminate use across all cancers.
Ivermectin: Promising Biology, Limited Clinical Evidence
Ivermectin has attracted substantial interest as a repurposed oncology drug because laboratory studies have reported effects on cancer-cell proliferation, apoptosis and signaling pathways including Wnt/β-catenin and Akt/mTOR.
These findings provide hypotheses for further research, but they should not be confused with demonstrated clinical benefit.
A 2025 review of ivermectin in oncology concluded that the preclinical evidence is interesting but that human clinical evidence remains limited, with no large randomized trials demonstrating that ivermectin improves cancer outcomes.
Importantly, the current evidence does not establish ivermectin as a treatment for desmoplasia. Any discussion of ivermectin in this context should therefore remain experimental and hypothesis-generating.
Mebendazole and Fenbendazole
Mebendazole and fenbendazole belong to the benzimidazole family and have generated interest in cancer research because of laboratory findings involving microtubules, cellular metabolism, signaling and other mechanisms.
The important scientific question is whether these mechanisms translate into meaningful clinical outcomes in humans.
At present, evidence for anticancer activity remains substantially stronger at the mechanistic and preclinical levels than at the level of high-quality randomized clinical trials.
Neither drug should therefore be presented as a proven method for breaking the desmoplastic shield.
Their potential value belongs in the broader repurposed-drug research pipeline: inexpensive existing molecules can sometimes reveal new biological vulnerabilities, but promising mechanisms require rigorous clinical validation.
Supplements and Nutraceuticals Under Investigation
Several dietary compounds have been investigated for effects on inflammation, oxidative stress, cellular signaling and the tumor microenvironment.
Curcumin
Investigated for inflammatory signaling, NF-κB-related pathways, fibrosis and cancer-cell signaling.
EGCG
The major catechin in green tea has been studied for effects on signaling, angiogenesis and the extracellular environment.
Sulforaphane
A compound derived from cruciferous vegetables being studied for redox, epigenetic and cellular-defense pathways.
Omega-3 fatty acids
Investigated for inflammatory and immune effects, although anticancer treatment claims remain unproven.
Quercetin
Studied for inflammatory signaling, oxidative stress, cellular senescence and other pathways.
Vitamin D
VDR-mediated stromal biology is particularly relevant to pancreatic cancer research.
Could Curcumin Help Remodel the Tumor Microenvironment?
Curcumin has attracted interest because it interacts with multiple inflammatory and signaling pathways rather than acting on a single molecular target.
Experimental studies have investigated its effects on NF-κB, STAT3, TGF-β and other pathways involved in inflammation and fibrosis.
However, one of the major limitations is bioavailability. The concentrations that produce effects in cell experiments do not necessarily correspond to achievable concentrations in human tumors.
Consequently, curcumin is best viewed as a research candidate rather than a clinically established stromal therapy.
Could Green Tea Catechins and EGCG Affect the Tumor Microenvironment?
Epigallocatechin gallate (EGCG), a major catechin in green tea, has been investigated for effects on tumor signaling, angiogenesis, inflammation and extracellular-matrix biology.
These mechanisms make EGCG scientifically interesting within a systems-oncology framework. But again, mechanistic plausibility is not equivalent to demonstrated survival benefit.
Supplement formulation, absorption and drug interactions are also important considerations.
The Combination Strategy: Tumor + Stroma + Metabolism + Immunity
The most interesting implication of desmoplasia research may not be a single “anti-stroma” drug.
Instead, cancer therapy may increasingly involve multi-layer combinations designed to address several biological barriers simultaneously.
Layer 1 — Cancer Cells
Target oncogenic signaling, DNA repair, cell division or other tumor-specific vulnerabilities.
Layer 2 — Stroma
Normalize extracellular matrix, fibroblast signaling, vascular function or abnormal tissue mechanics.
Layer 3 — Metabolism
Investigate glucose, insulin, mitochondrial and nutrient-signaling dependencies where biologically appropriate.
Layer 4 — Immunity
Improve antigen presentation, T-cell activity and immune-cell access while reducing immunosuppressive signaling.
This is the fundamental systems-medicine idea: cancer is simultaneously a cellular, metabolic, stromal and immune disease.
A treatment that kills tumor cells may become more effective if the surrounding microenvironment is simultaneously remodeled to improve drug penetration and immune access.
The Pancreatic Cancer Example
Pancreatic ductal adenocarcinoma is one of the clearest examples of this problem.
The tumor contains extensive non-malignant stromal tissue, including fibroblasts, extracellular matrix and immune populations. Recent research emphasizes the complex communication between fibroblasts, macrophages and cancer cells.
This complexity helps explain why therapies that work effectively in other tumor types may perform poorly in pancreatic cancer.
It also explains why the next generation of pancreatic cancer research increasingly focuses on tumor microenvironment reprogramming, rather than targeting the cancer cell alone.
Evidence Hierarchy: Promise Is Not Proof
One of the biggest problems in online cancer information is the tendency to treat laboratory evidence as clinical evidence.
A more useful framework is:
- E0 — Hypothesis: biological theory without direct experimental evidence.
- E1 — Mechanistic: biochemical or pathway-level evidence.
- E2 — Cell models: cancer-cell or stromal-cell experiments.
- E3 — Animal models: evidence in living organisms.
- E4 — Human observational or early clinical evidence: signals in patients but substantial uncertainty remains.
- E5 — High-quality clinical evidence: randomized or otherwise rigorous evidence demonstrating meaningful patient benefit.
What We Know — and What We Don't
What is increasingly clear
- The tumor microenvironment can influence cancer progression and treatment response.
- Desmoplasia is particularly important in pancreatic ductal adenocarcinoma.
- Cancer-associated fibroblasts are heterogeneous and biologically complex.
- Some stromal components can promote tumor progression while others may restrain it.
- Stromal normalization is a more sophisticated concept than indiscriminate stromal depletion.
- Repurposed medicines can provide useful experimental tools for testing TME hypotheses.
What remains uncertain
- Which patients benefit from stromal-targeting strategies?
- Which CAF populations should be targeted—and which should be preserved?
- Which biomarkers identify tumors with stromal dependence?
- Can stromal remodeling reliably improve chemotherapy delivery?
- Can stromal remodeling convert immunologically cold tumors into responsive tumors?
- Which repurposed drugs can produce clinically meaningful benefits?
- Can combinations improve survival without increasing unacceptable toxicity?
Where the Field Is Heading
The future of desmoplasia research is likely to become increasingly personalized.
Rather than asking:
“What drug breaks the tumor shield?”
researchers may increasingly ask:
“Which components of this patient's tumor microenvironment are creating therapeutic resistance, and which intervention can modify them without removing protective stromal functions?”
Advances in single-cell sequencing, spatial transcriptomics, imaging, proteomics and artificial intelligence are making it increasingly possible to map the cellular architecture of individual tumors.
This could eventually allow clinicians to classify tumors not only by their cancer-cell mutations, but also by their stromal phenotype, immune phenotype and metabolic phenotype.
Tumor genotype + tumor phenotype + immune phenotype + stromal phenotype + metabolic phenotype = a more complete treatment map.
A Systems-Oncology Model for the Desmoplastic Shield
A useful conceptual model is to view the tumor as five interconnected systems:
- Genomic system: KRAS, TP53, BRCA and other molecular alterations.
- Metabolic system: glucose, insulin, mitochondria, amino acids and nutrient availability.
- Stromal system: CAFs, collagen, hyaluronan and extracellular matrix.
- Immune system: T cells, macrophages, dendritic cells and immune checkpoints.
- Vascular system: perfusion, oxygenation and drug delivery.
These systems interact continuously. Therefore, a combination that affects two or more systems may eventually prove more effective than targeting a single pathway in isolation.
Bottom Line
The desmoplastic shield is real—but it is not simply a wall that needs to be demolished.
The tumor microenvironment is a dynamic ecosystem containing both tumor-promoting and tumor-restraining components. The most promising direction may therefore be selective stromal normalization and reprogramming.
Losartan provides an intriguing example of repurposing a cardiovascular drug to investigate stromal biology. Vitamin D receptor signaling offers another route for studying fibroblast and stellate-cell behavior. Metformin and other repurposed medicines raise broader questions about metabolic remodeling. Ivermectin, mebendazole and fenbendazole remain experimental candidates whose anticancer mechanisms require much stronger clinical validation.
Supplements such as vitamin D, curcumin, EGCG, sulforaphane, omega-3 fatty acids and quercetin are similarly best viewed according to the strength of their evidence rather than the attractiveness of their mechanisms.
The ultimate goal is not to replace conventional oncology. It is to understand whether tumor cells, metabolism, stroma, immunity and drug delivery can be addressed as an integrated system.
That may represent one of the next major frontiers in precision and metabolic oncology.
For patients and families, the most useful approach is to understand cancer from multiple perspectives—including prevention, early detection, tumor biology, biomarkers, treatment options, immunotherapy, metabolic health and emerging therapies. (OneDayMD cancer framework)
Frequently Asked Questions
What is the desmoplastic shield in cancer?
The term describes the dense fibroinflammatory tumor microenvironment surrounding certain cancers. It can include cancer-associated fibroblasts, collagen, hyaluronan, blood vessels and immune cells. In pancreatic cancer, this environment can influence drug delivery, immune access and tumor behavior.
Does desmoplasia make cancer harder to treat?
It can. Desmoplastic and fibroinflammatory environments can contribute to abnormal tissue mechanics, impaired perfusion, immune suppression and therapeutic resistance. However, the biology differs between cancers and even between patients with the same cancer.
Can losartan break down pancreatic cancer stroma?
Losartan has been investigated as a stromal-modulating strategy. A phase 2 pancreatic cancer study combining losartan with FOLFIRINOX and chemoradiotherapy produced encouraging surgical outcomes, but because the study was single-arm, it does not prove that losartan itself caused the benefit.
Does vitamin D treat pancreatic cancer?
No. Vitamin D receptor signaling is an important area of pancreatic cancer research, and vitamin D analogues have produced interesting stromal effects in experimental models. However, ordinary vitamin D supplementation has not been established as a pancreatic cancer treatment.
Can ivermectin break the tumor microenvironment?
There is currently insufficient clinical evidence to make that claim. Ivermectin has demonstrated anticancer effects in laboratory studies, but human evidence remains limited and does not establish clinical efficacy against cancer or desmoplasia.
Are supplements proven to break down tumor fibrosis?
No. Several compounds have interesting laboratory mechanisms involving inflammation, fibrosis or cellular signaling, but this should not be interpreted as proof that supplements can remodel a patient's tumor stroma or improve cancer survival.
What is the future of stromal targeting?
The field is moving toward selective stromal reprogramming, biomarker-guided therapy and combinations that address tumor cells, extracellular matrix, immune suppression, metabolism and vascular function together.
Scientific References and Further Reading
- Kung HC, Zheng KW, Zimmerman JW, et al. The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities. Nature Reviews Clinical Oncology. 2025.
- Arnold F, Del Vecchio A, Hussain Z, et al. Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment. Nature Reviews Cancer. 2026.
- Xiao Z, Puré E. The fibroinflammatory response in cancer. Nature Reviews Cancer. 2025.
- Huang H, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology.
- NCI. Vitamin D and Cancer. National Cancer Institute.
- NCI. Diets, Supplements, and Cancer. National Cancer Institute.
- Patel Y, Chawla J, Parmar MS. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? Current Oncology Reports. 2025.
- Gorchs L, et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Scientific Reports. 2020.
- Justus Hope. Why Starving Cancer Doesn't (Usually) Work. Substack. 2026
Editorial note: This article is intended for education and research discussion. It does not provide individualized medical advice, diagnosis or treatment recommendations. Evidence levels can change as clinical trials are published.
.png)
.png)
Comments
Post a Comment